ImmuCell Corporation (NASDAQ:ICCC)
| Market Cap | $97.63M+77.7% |
| Revenue (ttm) | $33.21M+19.6% |
| Net Income | $1.88M-19.1% |
| EPS | $0.20-22.4% |
| Shares Out | 9.08M |
| PE Ratio | 53.75 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,422 |
| Open | $10.66 |
| Previous Close | $10.22 |
| Day's Range | $10.50 - $10.75 |
| 52-Week Range | $4.52 - $12.10 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 23, 2027 |
About ICCC
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Feb 23, 2027Earnings report
$ICCC stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ICCC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ICCC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ICCC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ICCC Revenue by Segment
| Product sales | $8.04M | 64.19% |
| Costs of goods sold | $4.48M | 35.81% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ICCC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ICCC from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ICCC
| VTIVanguard Morningstar Total Stock Market ETF | $1.77M |
| VXFVanguard Extended Market ETF | $774.07K |
| IWCiShares Micro-Cap ETF | $195.16K |
| DFACDimensional - US Core Equity 2 ETF | $188.43K |
| DFATDimensional - US Targeted Value ETF | $76.71K |
| DXUVU.S. Vector Equity Portfolio ETF Class Shares | $30.54K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ICCC’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strong Q3 sales growth of 46% demonstrates solid business momentum; preliminary earnings beat expectations with notable revenue increase.
